Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

3

Indication details

Combined Agent(s)
Gemcitabine + cisplatin
Control Arm
Placebo + gemcitabine + cisplatin
Therapeutic Indication
First-line treatment of recurrent or metastatic nasopharyngeal carcinoma
Tumour Type
Head and neck cancer
Tumour Sub-type
Nasopharyngeal carcinoma
Tumour Stage
Recurrent or metastatic
Trial Name
CAPTAIN-1st
NCT Number
NCT03707509
Trial Phase
Phase III

Approval details

FDA Approval
Not FDA approved
EMA Approval
Not EMA approved
Comment
Approved in China by the National Medical Products Administration

Primary Outcome(s)

Primary Outcome(s)
PFS
Evaluated Outcome
PFS
Form(s)
Form 2b

Outcome Data

PFS Control
6.9 months (prespecified interim analysis)
PFS Gain
3.9 months
PFS HR
0.51 (0.37-0.69)

Adjustments

QoL Comment
QoL not a prespecified endpoint
Toxicity Comment
4% vs 1% treatment-related deaths (p=0.21, not significant)

Score (after adjustments)

Preliminary non-curative score

3

Non-curative score

3

Comment
Not EMA or FDA approved.

Approved in China by the National Medical Products Administration.

Scorecard details

ESMO-MCBS version
ESMO-MCBS v1.1
Scorecard ID
353
Scorecard version
1
Issue date
22.09.2022
Camrelizumab CAPTAIN-1st

PRELIMINARY SCORE

PFS

ADJUSTMENTS

Camrelizumab CAPTAIN-1st

SCORE

Overall Survival / Disease-Free Survival / Pathological Complete Response
Overall Survival
3
Progression-Free Survival
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Overall Response Rate / Duration of Response
Head and neck cancer
First-line treatment of recurrent or metastatic nasopharyngeal carcinoma
Camrelizumab + Gemcitabine + cisplatin
Placebo + gemcitabine + cisplatin

My watchlist

    pdf
    pptx

    Legend

    Information about symbols, abbrevations and color codes

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

    • Analytics cookies help us improve our website by collecting and reporting information on its usage.

    • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.